Uncertainty about the outlook due to raw material prices, inflation and foreign exchange movements
First written in FY2025-H1. 2 of 5 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 40 of 57 companies on the "Worse" side.
16 other companies' latest entry also says "Other".
- FY2026Explicitly identified the risk of price increases for pharmaceuticals, medical consumables and medical devicesAnnual report
「Amid the recent global surge in raw material and transportation costs, manufacturers have been raising prices successively for pharmaceuticals, medical consumables and medical devices,」
In addition to conventional inflation and rising raw material prices, rising procurement prices for medical-related products have been identified as a specific business risk. - 2026-05-13RestatedEarnings
「The outlook remains uncertain due to higher raw-material prices associated with U.S. tariff policies and escalating tensions in the Middle East, as well as continuing price inflation.」
Uncertainty arising from U.S. tariff policies, higher raw-material prices and inflation has been reiterated. - FY2026-H1U.S. tariff policy explicitly citedAnnual report
「Meanwhile, the outlook remains uncertain due to U.S. tariff policy, soaring raw material prices and continued inflation, among other factors.」
In addition to raw material prices and inflation, explicitly identifies U.S. tariff policy as a source of uncertainty. - FY2025RestatedAnnual report
「The outlook remains uncertain due to soaring raw material prices, inflation and changes in the international trade environment resulting from U.S. economic and foreign policy, among other factors.」
Restates uncertainty in the external environment, including raw material prices and inflation. - FY2025-H1First statedAnnual report
「The outlook remains uncertain due to soaring raw material prices, inflation and foreign exchange movements, among other factors.」
Identifies soaring raw material prices and inflation as risks in the external environment.